首发精神分裂症谱系障碍抗精神病药维持治疗停药后10年随访的长期影响
该研究对178例首发精神病且阳性症状完全缓解的患者进行10年随访,比较早期停药与维持治疗(喹硫平400mg/日)12个月后的长期结局。
要点
- 首发精神病完全缓解后早期停用抗精神病药与10年不良结局风险增加相关。
- 自杀是随访期唯一严重不良事件,停药组4例,维持组2例。
核心结论
- 对于首发精神病且对治疗有完全初始反应的患者,继续用药至少前3年可降低复发和不良长期临床结局的风险。
研究设计与样本
- 10年随访研究,基于2003年9月5日至2014年12月30日在香港7个中心进行的随机双盲试验,纳入178例首发精神病患者。
- 患者经至少1年抗精神病药治疗阳性症状完全缓解后,随机接受维持治疗(n=89,口服喹硫平400mg/日)或早期停药(n=89,安慰剂)12个月,之后接受自然治疗。
- 主要结局为10年时各组良好或不良长期临床结局的比例,不良结局定义为持续精神病症状、需氯氮平治疗或自杀死亡的复合指标。
主要发现
- 随访期唯一严重不良事件为自杀,早期停药组4例(4%),维持组2例(2%)。
临床怎么用
- 对首发精神病且初始治疗完全缓解的患者,建议至少前3年继续抗精神病药维持治疗以降低复发和不良长期结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term consequences of discontinuing antipsychotic medication after successful treatment of first-episode psychosis are not well studied. We assess the relation between early maintenance therapy decisions in first-episode psychosis and the subsequent clinical outcome at 10 years. METHODS: This is a 10 year follow-up study, spanning Sept 5, 2003, to Dec 30, 2014, of a randomised, double-blind trial in seven centres in Hong Kong in which 178 patients with first-episode psychosis with full positive symptom resolution after at least 1 year of antipsychotic treatment were given maintenance treatment (n=89; oral quetiapine 400 mg daily) or early treatment discontinuation (n=89; placebo) for 12 months. After the trial, patients received naturalistic treatment. Overall this cohort of patients will have received about 3 years of treatment before entering the follow-up phase of the study: about 2 years of maintenance treatment before study entry and 1 year of treatment in the trial. The primary outcome of this follow-up was the proportion of patients in each group (including those for whom direct follow-up was not available) with good or poor long-term clinical outcomes at 10 years, with poor outcome defined as a composite of persistent psychotic symptoms, a requirement for clozapine treatment, or death by suicide. The randomised trial was registered with ClinicalTrials.gov, number NCT00334035, and the follow-up study was registered with ClinicalTrials.gov, number NCT01926340. FINDINGS: Poor 10 year clinical outcome occurred in 35 (39%) of 89 patients in the discontinuation group and 19 (21%) of 89 patients in the maintenance treatment group (risk ratio 1·84, 95% CI 1·15-2·96; p=0·012). Suicide was the only serious adverse event that occurred in the follow-up phase (four [4%] patients in the early discontinuation group vs two [2%] in the maintenance group). INTERPRETATION: In patients with first-episode psychosis with a full initial response to treatment, medication continuation for at least the first 3 years after starting treatment decreases the risk of relapse and poor long-term clinical outcome. FUNDING: Food and Health Bureau, Research Grants Council of Hong Kong, and AstraZeneca.
引用
- Hui CLM, Honer WG, Lee EHM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018. PMID: 29551618. doi:10.1016/S2215-0366(18)30090-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。